Due to its role in complement activation, innate immunity, and chronic inflammation, CD35 has become a trending molecule in cancer predisposition studies, as attested to by studies that have been conducted on gallbladder cancer, nasopharyngeal carcinoma, non-small cell lung cancer, and gastric cancer (24–27). Here, CR1 is linked to gastric cancer.